Stem Cells International

Stem Cells, Inflammation, and Fibrosis


Publishing date
20 Nov 2015
Status
Published
Submission deadline
03 Jul 2015

1University of Kragujevac, Kragujevac, Serbia

2Newcastle University, Newcastle, UK


Stem Cells, Inflammation, and Fibrosis

Description

Most organs are susceptible to fibrotic diseases and currently fibroproliferative diseases are believed to be responsible for around 45% of deaths in developed countries. Although considerable efforts are being devoted to the search for antifibrotic treatments, there are currently few effective therapies for fibrotic diseases that do not result in severe secondary effects.

Last decades’ preclinical and clinical trials proposed stem cells as novel therapeutic agents for the treatment of fibroproliferative diseases. Recently, induced pluripotent stem cells (iPSC) and mesenchymal stem cell (MSC) as well as their secretomes have been investigated as a novel therapeutic approach for the treatment of fibrotic diseases. MSC produces cytokines, chemokines, and growth factors that robustly regulate cell behavior in a paracrine fashion during the remodeling process. Due to their immunomodulatory effects and their ability to act on profibrotic factors such as oxidative stress, hypoxia, and the transforming growth factor-β1 pathway, MSC has already been highlighted in preclinical and clinical studies of liver cirrhosis, kidney fibrosis, pulmonary fibrosis, postmyocardial infarction remodeling, etc. However, there are several obstacles, including poor engraftment and unwanted differentiation into myofibroblasts, which should be addressed for safe therapeutic use of MSC in the treatment of fibroproliferative diseases.

In this special issue, we invite investigators to contribute with original research articles as well as review articles that provide novel insights about possible role of stem cells in modulation of inflammation and fibrosis.

Potential topics include, but are not limited to:

  • Factors and parameters that modulate anti-inflammatory and antifibrotic characteristics of stem cells
  • The balance between proinflammatory and anti-inflammatory phenotype of MSC in the cell therapy of inflammatory and fibroproliferative diseases
  • Cellular and molecular mechanisms involved in MSC-mediated attenuation of liver cirrhosis
  • Stem cell mediated mechanisms involved in myocardial remodeling after ischemic injury
  • The role of MSC for prevention of fibrosis in kidney transplantation
  • Pericyte-mediated mechanisms involved in kidney fibrosis
  • iPSC and MSC as a novel therapeutic agents for the treatment of pulmonary fibrosis
  • Perspectives and obstacles for stem cell-based therapy of inflammation and fibrosis

Articles

  • Special Issue
  • - Volume 2016
  • - Article ID 3891386
  • - Editorial

Stem Cells, Inflammation, and Fibrosis

Vladislav Volarevic | Majlinda Lako | Miodrag Stojkovic
  • Special Issue
  • - Volume 2016
  • - Article ID 2640746
  • - Research Article

Pharmacological Inhibition of Gal-3 in Mesenchymal Stem Cells Enhances Their Capacity to Promote Alternative Activation of Macrophages in Dextran Sulphate Sodium-Induced Colitis

Bojana Simovic Markovic | Aleksandar Nikolic | ... | Vladislav Volarevic
  • Special Issue
  • - Volume 2016
  • - Article ID 6937976
  • - Review Article

The Immunomodulatory Effects of Mesenchymal Stem Cells in Prevention or Treatment of Excessive Scars

Bommie Florence Seo | Sung-No Jung
  • Special Issue
  • - Volume 2016
  • - Article ID 1492694
  • - Research Article

TGF-β1 Induces the Dual Regulation of Hepatic Progenitor Cells with Both Anti- and Proliver Fibrosis

Ai-Ting Yang | Dou-Dou Hu | ... | Hong You
  • Special Issue
  • - Volume 2016
  • - Article ID 4682875
  • - Research Article

The Comparison of the Immunologic Properties of Stem Cells Isolated from Human Exfoliated Deciduous Teeth, Dental Pulp, and Dental Follicles

Selin Yildirim | Noushin Zibandeh | ... | Tunc Akkoc
  • Special Issue
  • - Volume 2016
  • - Article ID 1628352
  • - Research Article

Delta-Like-1 Changes the Immunomodulatory Property of OP9 Cells

Lei Zhang | Rui-Jie Dang | ... | Nan-Zhu Fang
Stem Cells International
 Journal metrics
Acceptance rate45%
Submission to final decision76 days
Acceptance to publication35 days
CiteScore3.800
Impact Factor3.902
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.